Interim analysis, phase 3 (532 Chinese patients, untreated advanced squamous NSCLC): ivonescimab vs tislelizumab, each with chemotherapy, gave median overall survival (key secondary endpoint) 27·9 vs 23·7 months, HR 0·66. Grade ≥3 treatment-related AEs 69% vs 59%.
RCTn = 532
Lu et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China